MedPath

A clinical trial to study the effects of Beclomethasone in patients with Asthma

Phase 3
Completed
Conditions
Health Condition 1: null- Asthma
Registration Number
CTRI/2011/11/002176
Lead Sponsor
Glenmark Pharmaceuticals Ltd
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
280
Inclusion Criteria

1. Male or female patient aged between 18 to 70 years with clinical diagnosis of mild to moderate asthma

2. The patient provides written informed consent to participate in the study

3. FEV1 between 60% and 80% of the predicted value

4. Patient willing to perform all study related procedures including the use of study inhalers, spirometer and peak flow meter.

5. Positive response to the reversibility test

6. Negative urine pregnancy test at screening visit, in women of child bearing age group and willing to use acceptable contraceptive measures during the study period or women who have been permanently sterilized or attained menopause. Male patients should use double barrier contraceptive measures

Exclusion Criteria

1. Inability to carry out pulmonary function testing

2. Chronic Obstructive Pulmonary Disease (COPD)

3. Pregnant or lactating women

4. Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients

5. History of near fatal asthma exacerbation

6. Evidence of severe asthma exacerbation or symptomatic infection of the airways in the previous 4 weeks

7. Active smoker

8. Subjects who are using any medication or has any disease which in the judgment of the investigator will interfere with the conduct or interpretation of the study

9. Presence of severe co-morbidities, such as cardiovascular, renal, liver, neurological, neoplastic, hematological, endocrinal, infectious, dermatological, neurological or psychiatric disease or chronic respiratory disease other than asthma

10. History of Diabetes mellitus

11. Clinically significant ECG Abnormality at baseline

12. History of alcohol or drug abuse

13. Known history of HPA axis disease or malfunctioning

14. Patients who have undergone major surgery in the previous 4 weeks

15. Participation in an investigational drug trial within 3 months of screening

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath